This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Incyte Presents Results From A Phase I Trial Of INCB024360, A Novel Oral Inhibitor Of Indoleamine Dioxygenase-1 (IDO1), At ASCO

Incyte Corporation (Nasdaq: INCY) presented preliminary results today from the ongoing Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. IDO1 expression in human tumors is associated with poor prognosis, and IDO1 inhibition may provide a new approach to increase survival in patients with a variety of solid tumors.

“For cancer patients, elevated IDO levels correlate with poor outcomes. A compound, such as INCB024360, which can significantly inhibit IDO levels at doses that appear well-tolerated in a Phase I study, may offer a new therapeutic approach for these patients. We look forward to seeing this hypothesis tested in upcoming Phase II trials in patients with advanced ovarian cancer and advanced melanoma, a cancer where immunomodulatory therapies have promise,” stated presenting author Gregory Beatty, MD, PhD, an Assistant Professor in the Department of Medicine, Hematology/Oncology Division, at the Abramson Cancer Center of the University of Pennsylvania Perelman School of Medicine in Philadelphia.

The findings of the Phase I study were reported during an oral presentation, Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. The Phase I study of INCB024360 is an open-label, single-agent dose-escalation trial in patients with advanced cancers. The preliminary findings confirmed significant IDO1 expression in various tumors, including bladder, colorectal and breast cancers. Using two independent assays, IDO1 inhibition was observed in all patients receiving the compound, and treatment with INCB024360 resulted in greater than 90 percent inhibition of IDO1 activity when administered at doses above 300 mg twice a day. The compound is generally well-tolerated at these doses with the most common adverse events being grade 1 and 2 fatigue. A maximum tolerated dose has not been identified.

The slides used during the presentation can be accessed at: 2012 ASCO - INCB024360 presentation.

About Indoleamine Dioxygenase-1 (IDO1)

IDO1 is an enzyme that is expressed in tumor cells and in activated immune cells. IDO1 expression dampens the immune response by degrading the amino acid tryptophan and rendering tumor-specific cytotoxic T lymphocytes functionally inactive or unable to attack a person’s cancer cells. In preclinical models, blocking IDO1 activity can directly influence the ability of tumor-bearing animals to reject tumors, and IDO1 inhibition increases the efficacy of chemotherapeutic agents without increased toxicity. These effects are not observed in immune deficient animals, suggesting that the results depend on the presence of an active immune system. IDO1 is overexpressed by a variety of human tumor types and is chronically activated in some patients with cancer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs